Appendix Table 4.

Standardized 48-week risk differences and risk ratios of COVID-19 outcomes by NRTI combination in HIV-positive individuals,^* CoVIHd Collaboration, Spain, February-December 2020

	Documented SARS-CoV-2 infection		Hospitalization due to COVID-19		ICU admission due to COVID-19		COVID-19 death
	Risk Differences (95% CI), %	Risk Ratios (95% CI)	Risk Differences (95% CI), %	Risk Ratios (95% CI)	Risk Differences (95% CI), %	Risk Ratios (95% CI)	Risk Differences (95% CI), %	Risk Ratios (95% CI)
TAF/FTC	0	1.00	0	1.00	0	1.00	0	1.00
TDF/FTC	0.34 (−0.28, 0.89)	1.08 (0.94, 1.21)	−0.25 (−0.52,0.003)	0.73 (0.47, 1.00)	−0.06 (−0.12, 0.02)	0.40 (0.15, 1.26)	−0.03 (−0.06, 0.04)	0.45 (0.28, 2.14)
ABC/3TC	0.87 (0.40, 1.32)	1.20 (1.09, 1.32)	0.28 (0.03, 0.49)	1.30 (1.03, 1.61)	0.05 (−0.03, 0.14)	1.51 (0.77, 3.04)	0.07 (0.01, 0.13)	2.23 (1.10, 5.77)
Other regimes	0.21 (−0.29, 0.72)	1.05 (0.93, 1.17)	−0.15 (−0.35, 0.06)	0.83 (0.64, 1.07)	−0.02 (−0.10, 0.05)	0.75 (0.24, 1.75)	0.003 (−0.04,0.06)	1.06 (0.40, 2.65)

^*Adjusted via standardization for age (in years, linear and quadratic terms), sex (male, female), transmission category (heterosexual, homo/bisexual, injecting drug use, other), country of origin (Spain, other), CD4 (<350, 350–500, >500 cells/mm3), and hypertension, diabetes, chronic renal disease, cardiovascular disease, and treatment with immunosuppressants or corticosteroids.